Indisetron - Misplaced Pages

Chemical compound Pharmaceutical compound

Indisetron
Clinical data

Trade names	Sinseron
Other names	N-3389
ATC code	none
Legal status
Legal status	Rx in Japan
Identifiers
IUPAC name N-nonan-7-yl]-1H-indazole-3-carboxamide
CAS Number	141549-75-9
PubChem CID	178039
ChemSpider	2302029
UNII	89RBZ66NVC
KEGG	D02632
ChEBI	CHEBI:135344
ChEMBL	ChEMBL2104994
Chemical and physical data
Formula	C₁₇H₂₃N₅O
Molar mass	313.405 g·mol
3D model (JSmol)	Interactive image
SMILES CN1C2CC(C(C1)N2C)NC(=O)C3=NNC4=CC=CC=C43
InChI InChI=1S/C17H23N5O/c1-21-9-12-7-11(8-13(10-21)22(12)2)18-17(23)16-14-5-3-4-6-15(14)19-20-16/h3-6,11-13H,7-10H2,1-2H3,(H,18,23)(H,19,20)/t11?,12-,13+ Key:MHNNVDILNTUWNS-YHWZYXNKSA-N

Indisetron (INN; trade name Sinseron) is a drug used for prophylaxis of chemotherapy-induced nausea and vomiting. It was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2004.

Indisetron exerts its effects as a dual serotonin 5-HT₃ and 5-HT₄ receptor antagonist.

References

"Indisetron". Inxight: Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
Tsukagoshi S (April 2005). "". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 32 (4): 567–73. PMID 15853230.

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.